Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease

Haemostasis

Volumn 27, Issue 6, 1998, Pages 269-277

  Hommes, D W ^a,b   Van Dullemen, H M ^b   Levi, M ^a,e   Van Der Ende, A ^a   Woody, J ^d   Tytgat, G N J ^b   Van Deventer, S J H ^a,c  

^a Ctr Hemostasis Thromb A

^b Department of Gastroenterology ^*

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d CENTOCOR INC   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Blood coagulation; Crohn's disease; Cytokines; Fibrinolysis; Tumor necrosis factor

Indexed keywords

C A2; D DIMER; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ADULT; ANTIBODIES, MONOCLONAL; ANTITHROMBINS; BLOOD COAGULATION FACTORS; CROHN DISEASE; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PROTHROMBIN TIME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3543058090     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Morowitz DA, Allen LW, Kirschner JB: Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013-1021.
2. Wakefield AJ, Dhillon AP, Rowles PM, Sawyer AM, Pittilo RM, Lewis AAM, Pounder RE: Pathogenesis of Crohn's disease: Multifocal gastrointestinal infarction. Lancet 1989;ii: 1057-1062.
3. Bargin JA, Barker AW: Extensive arterial and venous thrombosis complicating chronic colitis. Arch Intern Med 1936;58:17-31.
4. Graef V, Baggcntoss AH, Sauer LG, Spitell JA: Venous thrombosis occurring in nonspecific ulcerative colitis. Arch Intern Med 1966;117: 377-382.
5. Talbot RW, Heppell J, Dozois RR, Beart RW: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-144.
6. Koenigs KP, McPhedran P, Spiro HM: Thrombosis in inflammatory bowel disease. J Clin Gastroenterol 1987;9:627-631.
7. Lam A, Borda IT, Inwood MJ, Thomson S: Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975;68: 245-251.
8. Lake AM, Stauffer JA, Stuart MJ: Hemostatic alterations in inflammatory bowel disease: Response to therapy. Am J Dig Dis 1978;23: 897-902.
9. Schneiderman JH, Sharpe JA, Sutton DMC: Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979; 5:331-337.
10. Aadland E, Odegaard OR, Roseth A, Try K: Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1992;27:957-960.
11. Gosh S, Mackie MJ, McVerry BA, Galloway M, Ellis A, McKay K: Chronic inflammatory bowel disease, deep venous thrombosis and antithrombin activity. Acta Haematol 1983;70:50-53.
12. Stevens TRJ, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS: Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992;33:502-506.
13. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
14. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537.
15. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ: Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type I plasminogen activator inhibitor. J Biol Chem 1988;263:5797-5803.
16. van Hinsbergh VMW, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis JJ: Tumor necrosis factor increases the production of plasminogen activator in human endothelial cells in vitro and in rats in vivo. Blood 1988;72:1467-1473.
17. van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;22:1622-1627.
18. van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174:729.
19. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-917.
20. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT: Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
21. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT: Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993;46:757-760.
22. Isaacs KL, Sartor RB, Haskill S: Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-1595.
23. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S: Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992;33: 1214-1219.
24. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-1709.
25. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Peppercorn MA, Strom TB: Tumor necrosis factor-alpha, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-826.
26. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT: Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455-1466.
27. van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with an anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-135.
28. Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
29. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek S, Daddona P, et al: Construction and initial characterisation of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-1453.
30. Cejka J: Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982;94:631-636.
31. Beutler B, Cerami A: The biology of cachectin/TNF. A primary mediator of the host response. Annu Rev Immunol 1989;7:625-655.
32. van der Poll T, Levi M, van Deventer SJH, ten Cate H, Haagmans BL, Biemond B, Büller HR, Hack CE, ten Cate JW: Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994;83:446-451.
33. van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJH, Eerenberg AJM, de Groot E, Jansen J, Gallati H, Buller HR, ten Cate JW, Aarden LA: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179:1253-1259.
34. Mahida YR, Kurlak L, Gallagher A, Hawkey CJ: High circulating levels of interleukin-6 in active Crohn's disease but not in ulcerative colitis. Gut 1991;32:1531-1534.
35. Gross V, Andus T, Caesar I, Roth M, Scholmerich J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-519.
36. van der Poll, van Deventer SJH, Buller HR, ten Cate JW: Tumor necrosis factor induces von Willebrand factor release in healthy volunteers. Thromb Haemost 1992;67: 623-626.
37. Kahaleh MB, Osborn I, LeRoy EC: Increased factor VIII/von Willebrand factor and von Willebrand activity in scleroderma and Raynaud's phenomenon. Ann Intern Med 1981;94:482-484.